Jilidea

Abiraterone acetate, the active ingredient in Jilidea, is a CYP17 inhibitor presented as an oral tablet for oral use. It reduces androgen production and is indicated for the treatment of metastatic castration‑resistant prostate cancer in men who have progressed despite androgen‑deprivation therapy and improves overall survival outcomes.

GNH USA supplies Jilidea as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The company adheres to stringent quality standards and provides reliable sourcing for clinical use across multiple regions.

Abiraterone acetate is used to inhibit androgen biosynthesis in advanced prostate cancer.

- Metastatic castration‑resistant prostate cancer: prolongs overall survival and delays disease progression.

Abiraterone acetate may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Fatigue: persistent tiredness affecting daily activities. - Hypertension: elevated blood pressure requiring monitoring. - Nausea: upset stomach and possible vomiting.

Serious or Rare Side Effects: - Adrenal insufficiency: risk of cortisol deficiency. - Hepatic failure: significant liver injury. - Cardiac arrhythmia: irregular heart rhythm.

When prescribing Abiraterone acetate, several precautions should be observed to ensure patient safety. - Blood pressure monitoring: check regularly due to risk of hypertension. - Potassium level assessment: monitor for hypokalemia and supplement if needed. - Liver function tests: evaluate before and during therapy. - Concomitant glucocorticoid use: administer prednisone to mitigate mineralocorticoid excess. - Avoid strong CYP3A4 inhibitors: may increase drug exposure. - Store at room temperature: keep in original packaging, protect from moisture.

Abiraterone acetate interacts with several medications; awareness of these interactions helps prevent adverse effects.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): increase abiraterone levels. - Strong CYP3A4 inducers (e.g., rifampin, phenytoin): decrease efficacy. - Concomitant use with other CYP17 inhibitors: additive hormonal effects.

Moderate Interactions (Monitor Closely): - Antihypertensive agents: may require dose adjustment. - Potassium‑sparing diuretics: risk of hyperkalemia. - Warfarin: monitor INR for potential changes. - Moderate CYP3A4 azole antifungals: may modestly raise abiraterone levels.